Suggested remit - To appraise the clinical and cost effectiveness of netarsudil within its marketing authorisation for treating open angle glaucoma or ocular hypertension.
Status Awaiting development
Decision None selected
Process TA
ID number 1078

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 August 2020 - 03 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 December 2018 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of netarsudil for treating open angle glaucoma or ocular hypertension ID1078. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that is developing netarsudil, NICE has agreed that a consultation on the draft scope and holding a scoping workshop at this time would not be appropriate. Consequently the consultation on the draft scope will be closed and scoping workshop arranged for the 21 January 2019 will be cancelled. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.

For further information on our processes and methods, please see our CHTE processes and methods manual